Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Figg Website

William Douglas Figg Sr., Pharm.D.

Selected Publications

1)  Shahbazi S, Peer CJ, Polizzotto MN, Uldrick TS, Roth J, Wyvill KM, Aleman K, Zeldis JB, Yarchoan R, Figg WD.
A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.
J Pharm Biomed Anal. 92: 63-8, 2014.
[Journal]
2)  Benazzi C, Al-Dissi A, Chau CH, Figg WD, Sarli G, de Oliveira JT, Gärtner F.
Angiogenesis in Spontaneous Tumors and Implications for Comparative Tumor Biology.
ScientificWorldJournal. 2014: 919570, 2014.
[Journal]
3)  Platz EA, Tangen CM, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Lucia MS, Thompson IM, Kristal AR.
Statin Drug Use Is Not Associated with Prostate Cancer Risk in Men who are Regularly Screened.
J. Urol. 2014.
[Journal]
4)  Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, Poondru S, Van Sant C, Keating A, Steinberg SM, Figg W, Giaccone G.
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Ann. Oncol. 24: 2601-6, 2013.
[Journal]
5)  Vargesson N, Mahony C, Erskine L, Niven J, Greig NH, Figg WD.
Reply to D’Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos.
Proc. Natl. Acad. Sci. U.S.A. 110: E4820, 2013.
[Journal]
6)  Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N.
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation.
Proc. Natl. Acad. Sci. U.S.A. 106: 8573-8, 2009.
[Journal]
7)  Cook KM, Hilton ST, Mecinovic J, Motherwell WB, Figg WD, Schofield CJ.
Epidithiodiketopiperazines block the interaction between hypoxia inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism.
J. Biol. Chem. 2009.
[Journal]
8)  Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL.
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
J. Clin. Oncol. 28: 2070-6, 2010.
[Journal]
9)  Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD.
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Clin. Cancer Res. 18: 2099-107, 2012.
[Journal]
10)  Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD.
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Clin. Cancer Res. 14: 3312-8, 2008.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/1/2014.